News Keytruda in new lymphoma use leads latest CHMP decisions MSD keeps pressure on BMS with EU classical Hodgkin lymphoma indication.
News NICE rejects Opdivo in blood cancer, asks for more data Merck's rival Keytruda gets new US indication.
News BMS appoints new science chief in fall-out from Opdivo setba... Bristol-Myers Squibb’s (BMS) chief scientific officer Francis Cuss is to step down following the company's huge lung cancer setback with Opdivo last year, to be replaced by former Massachus
News Icahn takes stake in BMS, adding to takeover speculation Activist investor's intervention adds to buzz surrounding BMS.
News Is BMS the next pharma takeover target? Speculation mounting that Pfizer and others could try for $90 bn plus merger
News Heart trial success will give Xarelto edge Xarelto aces outcomes trial and could have edge over Boehringer and BMS rivals.
News GBL joins CVC in €10.7bn takeover bid for Recordati A consortium of investors has made a €10.7bn offer to take Italian pharma Recordati private, but some analysts are sceptical the deal will go through.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
